Papilocare® 21 Single-Dose Cannulas

This Papilocare 21 x 5ml single-dose cannula product variation is intended for a woman’s first month of application. The full application duration is 6 months, which can be extended for longer based on the medical advice. It is important to complete the full length of treatment in order to obtain the desired results. It is recommended to start treatment after menstruation.

What is Papilocare and how does it work?
Papilocare is the first clinically proven treatment solution for HPV-induced low grade (ASCUS, LSIL, CIN 1) lesions of the cervical transformation zone. The Coriolus versicolor-based vaginal gel is specifically formulated to activate the three modifiable HPV-induced low grade lesion repair factors.

• Re-epithelialisation of the cervical transformation zone
• Rebalancing the vaginal microbiota
• Counteracting the non-inflammatory microenvironment that HPV creates.

Who can use Papilocare?
The use of Papilocare is recommended in women (over 18 years of age) infected by the human papillomavirus (HPV), independently of whether they have virus-induced lesions (ASCUS or LSIL).

Instructions for use:
Papilocare is supplied in single-use vaginal cannulas. Any cannula that appears open or broken should be discarded. The cannula is designed to aid in the product’s application. For application, lay on your back. The cannula should be inserted into the vagina, then press to release its contents. Then, remove it from the vagina, while continuing to press the cannula, in order to not suction out the product already applied. It is possible that a small amount of gel remains in the cannula. This does not mean that a dose less than what is recommended has been administered, as the cannula releases a sufficient amount to cover the cervical-vaginal mucosa (3 ml). Once the cannula is used, it should be discarded. A cannula should not be reused nor shared between two patients.

First month (21 x 5ml cannulas): Insert one cannula per day into the vagina, preferably before bedtime, for 21 consecutive days, then take the next 7 days off.
Months 2 to 6 (55 x 5ml cannulas): Insert one cannula into the vagina, preferably before bedtime every other day for 21 days. Then one single-dose cannula every other day for the 5 following months (off during the period). If you do not have periods, follow the same treatment plan outlined in the diagram.
The recommendation to pause treatment with Papilocare during menstruation has to do with patient comfort, and not because there is any clinical incompatibility. Papilocare is compatible with the use of condoms.

Can Papilocare® Vaginal Gel be used with a vaginal ring (NuvaRing or Estring)?
There is no data pertaining to Papilocare® Vaginal Gel in patients using vaginal contraceptives. Indeed, these patients have always been excluded from Papilocare® Vaginal Gel research studies (exclusion criteria: use of vaginal contraceptives or other vaginal hormonal treatments). Therefore, as a precaution, it is better not to use Papilocare® Vaginal Gel in patients wearing a vaginal contraceptive. In any case, as it is not an absolute contraindication, it will always be the doctor who assesses the benefits and risks and determines the timing of the prescription.

Storage: Papilocare should be kept between 2°C and 25°C. Keep out of reach of children.